Agilent Technologies Inc vs Innodata Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Innodata Inc trades at $62.99 (market cap $2.03B). The key difference: Agilent Technologies Inc is far larger — about 20.7× Innodata Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| A | INOD | |
|---|---|---|
Market Cap | $42.00B | $2.03B |
Sector | Health | Technology |
52-Week High | $157.20 | $121.50 |
52-Week Low | $110.24 | $34.45 |
Enterprise Value | $43.55B | $1.79B |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
INOD trades at $62.33, down 4.81% over 24 hours, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.41 versus $0.21 expected, driven by 58% revenue growth and AI demand expansion. Valuation ratios remain elevated, with a P/E of 48.24 and P/S of 6.79, reflecting high growth expectations. Recent news highlights AI-driven growth and leadership transition plans.
Outlook is positive due to robust AI momentum and earnings beats, but risks include premium valuation and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside from current levels. Investors should weigh growth potential against execution risks in a competitive AI services market.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →